Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:Butylparaben
go back to main search page
Accession:CHEBI:88542 term browser browse the term
Synonyms:related_synonym: 4-(Butoxycarbonyl)phenol;   4-Hydroxybenzoic acid butyl ester;   Aseptoform butyl;   Benzoic acid, 4-hydroxy-, butyl ester;   Benzoic acid, p-hydroxy-, butyl ester;   Butoben;   Butyl 4-hydroxybenzoate;   Butyl butex;   Butyl chemosept;   Butyl par asept;   Butyl paraben;   Butyl parahydroxybenzoate;   Butyl parahydroxybenzoate (JP15);   Butyl parahydroxybenzoate (TN);   Butyl parasept;   Butyl tegosept;   Butyl-p-hydroxybenzoate;   Butylparaben (NF);   Butylparaben (TN);   Butylparaben [usan];   FEMA 2203;   Formula=C11H14O3;   InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3;   InChIKey=QFOHBWFCKVYLES-UHFFFAOYSA-N;   Lexgard b;   N-Butyl 4-hydroxybenzoate;   N-Butyl hydroxybenzoate;   N-Butyl parahydroxybenzoate;   N-Butyl-p-hydroxybenzoate;   N-Butyl-paraben;   Nipabutyl;   P-Hydroxy butyl benzoate;   P-Hydroxybenzoic acid N-butyl ester;   P-Hydroxybenzoic acid butyl ester;   P-Hydroxybenzoic butyl ester;   Parasept;   Preserval b;   SMILES=CCCCOC(C1=CC=C(C=C1)O)=O;   SPF;   Solbrol b;   Tegosept B
 alt_id: CHEBI:31329
 xref: CAS:94-26-8;   HMDB:HMDB0032575;   KEGG:D01420;   LINCS:LSM-2161
 xref_mesh: MESH:C038091
 xref: PMID:18294789


show annotations for term's descendants           Sort by:
Butylparaben term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AARS2 alanyl-tRNA synthetase 2, mitochondrial increases expression EXP butylparaben results in increased expression of AARS2 mRNA CTD PMID:17121429 NCBI chr 6:44,298,731...44,313,347
Ensembl chr 6:44,298,731...44,313,347 		JBrowse link
G ABAT 4-aminobutyrate aminotransferase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ABAT mRNA CTD PMID:25607892 NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575 		JBrowse link
G ACAN aggrecan decreases expression ISO butylparaben results in decreased expression of ACAN mRNA CTD PMID:28527915 NCBI chr15:88,803,436...88,875,353
Ensembl chr15:88,803,436...88,875,353 		JBrowse link
G ACSL6 acyl-CoA synthetase long chain family member 6 increases expression EXP butylparaben results in increased expression of ACSL6 mRNA CTD PMID:17121429 NCBI chr 5:131,949,973...132,012,213
Ensembl chr 5:131,949,973...132,012,243 		JBrowse link
G ACTN1 actinin alpha 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ACTN1 mRNA CTD PMID:25607892 NCBI chr14:68,874,128...68,979,302
Ensembl chr14:68,874,128...68,979,440 		JBrowse link
G ADAM17 ADAM metallopeptidase domain 17 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA CTD PMID:25607892 NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732 		JBrowse link
G ADIPOQ adiponectin, C1Q and collagen domain containing multiple interactions
increases expression		 EXP
ISO		 butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]
butylparaben results in increased expression of ADIPOQ mRNA
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of ADIPOQ mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]		 CTD PMID:22956630 PMID:31016361 NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463 		JBrowse link
G ADM adrenomedullin decreases expression EXP butylparaben results in decreased expression of ADM mRNA CTD PMID:17121429 NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397 		JBrowse link
G ALPL alkaline phosphatase, biomineralization associated decreases expression
multiple interactions		 ISO butylparaben results in decreased expression of ALPL mRNA
NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]		 CTD PMID:28527915 NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410 		JBrowse link
G AR androgen receptor affects binding
affects expression
decreases expression		 ISO butylparaben binds to AR protein
butylparaben affects the expression of AR protein
butylparaben results in decreased expression of AR mRNA; butylparaben results in decreased expression of AR protein		 CTD PMID:20371976 PMID:26888303 PMID:27444704 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619 		JBrowse link
G ARHGAP9 Rho GTPase activating protein 9 increases expression EXP butylparaben results in increased expression of ARHGAP9 mRNA CTD PMID:17121429 NCBI chr12:57,472,269...57,488,824
Ensembl chr12:57,472,264...57,488,814 		JBrowse link
G ATF4 activating transcription factor 4 increases expression ISO butylparaben results in increased expression of ATF4 mRNA CTD PMID:36277366 NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683 		JBrowse link
G ATF6 activating transcription factor 6 increases expression EXP butylparaben results in increased expression of ATF6 protein CTD PMID:29319206 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574 		JBrowse link
G ATM ATM serine/threonine kinase affects expression EXP butylparaben affects the expression of ATM mRNA CTD PMID:24481588 NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102 		JBrowse link
G ATP5MG ATP synthase membrane subunit g increases expression EXP butylparaben results in increased expression of ATP5MG mRNA CTD PMID:17121429 NCBI chr11:118,401,606...118,409,847
Ensembl chr11:118,401,346...118,433,278 		JBrowse link
G ATR ATR serine/threonine kinase increases expression EXP butylparaben results in increased expression of ATR mRNA CTD PMID:24481588 NCBI chr 3:142,449,235...142,578,733
Ensembl chr 3:142,449,007...142,578,733 		JBrowse link
G AVP arginine vasopressin multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of AVP mRNA CTD PMID:34383603 NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724 		JBrowse link
G BCL2L1 BCL2 like 1 increases expression EXP butylparaben results in increased expression of BCL2L1 mRNA; butylparaben results in increased expression of BCL2L1 protein CTD PMID:24481588 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of BDNF mRNA CTD PMID:25607892 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058 		JBrowse link
G BGLAP bone gamma-carboxyglutamate protein decreases expression ISO butylparaben results in decreased expression of BGLAP mRNA CTD PMID:28527915 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317 		JBrowse link
G BSN bassoon presynaptic cytomatrix protein multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of BSN mRNA CTD PMID:25607892 NCBI chr 3:49,554,477...49,673,130
Ensembl chr 3:49,554,477...49,671,549 		JBrowse link
G CACNA1A calcium voltage-gated channel subunit alpha1 A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1A mRNA CTD PMID:25607892 NCBI chr19:13,206,442...13,506,479
Ensembl chr19:13,206,442...13,633,025 		JBrowse link
G CACNA1C calcium voltage-gated channel subunit alpha1 C multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA CTD PMID:25607892 NCBI chr12:1,970,780...2,697,950
Ensembl chr12:1,970,772...2,697,950 		JBrowse link
G CACNA1D calcium voltage-gated channel subunit alpha1 D multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA1D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1D mRNA CTD PMID:25607892 NCBI chr 3:53,494,611...53,813,733
Ensembl chr 3:53,328,963...53,813,733 		JBrowse link
G CACNA1E calcium voltage-gated channel subunit alpha1 E multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1E mRNA CTD PMID:25607892 NCBI chr 1:181,317,699...181,808,084
Ensembl chr 1:181,317,690...181,813,262 		JBrowse link
G CACNA1F calcium voltage-gated channel subunit alpha1 F multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1F mRNA CTD PMID:25607892 NCBI chr  X:49,205,063...49,233,340
Ensembl chr  X:49,205,063...49,233,371 		JBrowse link
G CACNA1G calcium voltage-gated channel subunit alpha1 G multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1G mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1G mRNA CTD PMID:25607892 NCBI chr17:50,560,715...50,627,474
Ensembl chr17:50,560,715...50,627,474 		JBrowse link
G CACNA1H calcium voltage-gated channel subunit alpha1 H multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1H mRNA CTD PMID:25607892 NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169 		JBrowse link
G CACNA1I calcium voltage-gated channel subunit alpha1 I multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1I mRNA CTD PMID:25607892 NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735 		JBrowse link
G CACNA2D1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA2D1 mRNA CTD PMID:25607892 NCBI chr 7:81,946,444...82,443,956
Ensembl chr 7:81,946,444...82,443,956 		JBrowse link
G CACNA2D2 calcium voltage-gated channel auxiliary subunit alpha2delta 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA CTD PMID:25607892 NCBI chr 3:50,362,613...50,504,244
Ensembl chr 3:50,362,613...50,504,244 		JBrowse link
G CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA CTD PMID:25607892 NCBI chr 3:54,122,552...55,074,557
Ensembl chr 3:54,122,552...55,074,557 		JBrowse link
G CACNB1 calcium voltage-gated channel auxiliary subunit beta 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB1 mRNA CTD PMID:25607892 NCBI chr17:39,173,453...39,197,669
Ensembl chr17:39,173,453...39,197,702 		JBrowse link
G CACNB2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA CTD PMID:25607892 NCBI chr10:18,140,424...18,543,557
Ensembl chr10:18,140,424...18,543,557 		JBrowse link
G CACNB3 calcium voltage-gated channel auxiliary subunit beta 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB3 mRNA CTD PMID:25607892 NCBI chr12:48,814,480...48,828,941
Ensembl chr12:48,813,794...48,828,941 		JBrowse link
G CACNG2 calcium voltage-gated channel auxiliary subunit gamma 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA CTD PMID:25607892 NCBI chr22:36,560,857...36,703,752
Ensembl chr22:36,560,857...36,703,752 		JBrowse link
G CACNG5 calcium voltage-gated channel auxiliary subunit gamma 5 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG5 mRNA CTD PMID:25607892 NCBI chr17:66,835,117...66,894,751
Ensembl chr17:66,835,117...66,894,751 		JBrowse link
G CACNG6 calcium voltage-gated channel auxiliary subunit gamma 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNG6 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG6 mRNA CTD PMID:25607892 NCBI chr19:53,991,149...54,012,666
Ensembl chr19:53,991,637...54,012,666 		JBrowse link
G CACNG8 calcium voltage-gated channel auxiliary subunit gamma 8 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG8 mRNA CTD PMID:25607892 NCBI chr19:53,962,937...53,990,215
Ensembl chr19:53,962,937...53,990,215 		JBrowse link
G CALB2 calbindin 2 increases expression EXP butylparaben results in increased expression of CALB2 mRNA CTD PMID:17121429 NCBI chr16:71,358,723...71,390,433
Ensembl chr16:71,358,713...71,390,436 		JBrowse link
G CAMK2B calcium/calmodulin dependent protein kinase II beta multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA CTD PMID:25607892 NCBI chr 7:44,217,154...44,326,013
Ensembl chr 7:44,210,019...44,334,577 		JBrowse link
G CARTPT CART prepropeptide multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in increased expression of CARTPT mRNA CTD PMID:34383603 NCBI chr 5:71,719,275...71,721,045
Ensembl chr 5:71,719,275...71,721,048 		JBrowse link
G CASK calcium/calmodulin dependent serine protein kinase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CASK mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CASK mRNA CTD PMID:25607892 NCBI chr  X:41,514,934...41,923,554
Ensembl chr  X:41,514,934...41,923,554 		JBrowse link
G CASP8 caspase 8 increases expression EXP butylparaben results in increased expression of CASP8 protein CTD PMID:24481588 NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836 		JBrowse link
G CAT catalase decreases activity
multiple interactions		 ISO butylparaben results in decreased activity of CAT protein
butylparaben inhibits the reaction [Triclosan results in increased activity of CAT protein]		 CTD PMID:29350491 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCNA1 cyclin A1 increases expression EXP butylparaben results in increased expression of CCNA1 mRNA CTD PMID:24481588 NCBI chr13:36,431,517...36,442,870
Ensembl chr13:36,431,520...36,442,870 		JBrowse link
G CCNA2 cyclin A2 increases expression EXP butylparaben results in increased expression of CCNA2 mRNA CTD PMID:24481588 NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883 		JBrowse link
G CCNB2 cyclin B2 increases expression EXP butylparaben results in increased expression of CCNB2 mRNA CTD PMID:24481588 NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045 		JBrowse link
G CCND1 cyclin D1 increases expression EXP butylparaben results in increased expression of CCND1 mRNA CTD PMID:23524099 PMID:24481588 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CCND3 cyclin D3 decreases expression
affects expression		 EXP butylparaben results in decreased expression of CCND3 mRNA
butylparaben affects the expression of CCND3 mRNA		 CTD PMID:24481588 NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357 		JBrowse link
G CCNE1 cyclin E1 affects expression EXP butylparaben affects the expression of CCNE1 mRNA CTD PMID:24481588 NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312 		JBrowse link
G CCNE2 cyclin E2 increases expression EXP butylparaben results in increased expression of CCNE2 mRNA CTD PMID:24481588 NCBI chr 8:94,880,224...94,896,693
Ensembl chr 8:94,879,770...94,896,678 		JBrowse link
G CD44 CD44 molecule (IN blood group) multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CD44 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CD44 mRNA CTD PMID:25607892 NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402 		JBrowse link
G CDC25A cell division cycle 25A increases expression EXP butylparaben results in increased expression of CDC25A mRNA CTD PMID:24481588 NCBI chr 3:48,157,146...48,188,417
Ensembl chr 3:48,157,146...48,188,417 		JBrowse link
G CDK2 cyclin dependent kinase 2 increases expression EXP butylparaben results in increased expression of CDK2 mRNA CTD PMID:24481588 NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789 		JBrowse link
G CDK4 cyclin dependent kinase 4 increases expression EXP butylparaben results in increased expression of CDK4 mRNA CTD PMID:24481588 NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013 		JBrowse link
G CDK6 cyclin dependent kinase 6 affects expression EXP butylparaben affects the expression of CDK6 mRNA CTD PMID:24481588 NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A decreases expression EXP butylparaben results in decreased expression of CDKN1A mRNA; butylparaben results in decreased expression of CDKN1A protein CTD PMID:24481588 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337 		JBrowse link
G CEBPA CCAAT enhancer binding protein alpha multiple interactions
increases expression		 ISO
EXP		 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of CEBPA mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]; Rimonabant inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA] CTD PMID:22956630 PMID:27659731 PMID:28527915 NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534 		JBrowse link
G CELF5 CUGBP Elav-like family member 5 increases expression EXP butylparaben results in increased expression of CELF5 mRNA CTD PMID:17121429 NCBI chr19:3,224,661...3,297,076
Ensembl chr19:3,224,661...3,297,076 		JBrowse link
G CHRDL1 chordin like 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CHRDL1 mRNA CTD PMID:25607892 NCBI chr  X:110,673,856...110,795,817
Ensembl chr  X:110,673,856...110,795,819 		JBrowse link
G CHST1 carbohydrate sulfotransferase 1 increases expression EXP butylparaben results in increased expression of CHST1 mRNA CTD PMID:17121429 NCBI chr11:45,647,689...45,665,622
Ensembl chr11:45,647,689...45,665,622 		JBrowse link
G CNTN3 contactin 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN3 mRNA CTD PMID:25607892 NCBI chr 3:74,262,568...74,614,659
Ensembl chr 3:74,262,568...74,614,659 		JBrowse link
G CNTN4 contactin 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA CTD PMID:25607892 NCBI chr 3:2,098,866...3,057,959
Ensembl chr 3:2,098,813...3,057,959 		JBrowse link
G COL10A1 collagen type X alpha 1 chain decreases expression ISO butylparaben results in decreased expression of COL10A1 mRNA CTD PMID:28527915 NCBI chr 6:116,118,909...116,217,144
Ensembl chr 6:116,118,909...116,158,747 		JBrowse link
G COL2A1 collagen type II alpha 1 chain decreases expression ISO butylparaben results in decreased expression of COL2A1 mRNA CTD PMID:28527915 NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554 		JBrowse link
G COL8A1 collagen type VIII alpha 1 chain increases expression EXP butylparaben results in increased expression of COL8A1 mRNA CTD PMID:17121429 NCBI chr 3:99,638,594...99,799,217
Ensembl chr 3:99,638,475...99,799,226 		JBrowse link
G COPS2 COP9 signalosome subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of COPS2 mRNA CTD PMID:25607892 NCBI chr15:49,122,727...49,155,599
Ensembl chr15:49,106,068...49,155,661 		JBrowse link
G CRH corticotropin releasing hormone multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] affects the expression of CRH mRNA CTD PMID:34383603 NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464 		JBrowse link
G CXCL3 C-X-C motif chemokine ligand 3 increases expression EXP butylparaben results in increased expression of CXCL3 mRNA CTD PMID:17121429 NCBI chr 4:74,036,589...74,038,689
Ensembl chr 4:74,036,589...74,038,807 		JBrowse link
G CYBA cytochrome b-245 alpha chain increases expression EXP butylparaben results in increased expression of CYBA mRNA CTD PMID:17121429 NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083 		JBrowse link
G CYCS cytochrome c, somatic increases expression EXP butylparaben results in increased expression of CYCS protein CTD PMID:29319206 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260 		JBrowse link
G CYP11A1 cytochrome P450 family 11 subfamily A member 1 decreases expression ISO butylparaben results in decreased expression of CYP11A1 mRNA; butylparaben results in decreased expression of CYP11A1 protein CTD PMID:26888303 NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646 		JBrowse link
G CYP11B1 cytochrome P450 family 11 subfamily B member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CYP11B1 mRNA CTD PMID:25607892 NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846 		JBrowse link
G CYP17A1 cytochrome P450 family 17 subfamily A member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP17A1 mRNA CTD PMID:25607892 NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472 		JBrowse link
G CYP19A1 cytochrome P450 family 19 subfamily A member 1 decreases expression
multiple interactions
increases expression
affects expression
increases activity		 ISO
EXP		 butylparaben results in decreased expression of CYP19A1 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP19A1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CYP19A1 mRNA
butylparaben results in decreased expression of CYP19A1 mRNA; butylparaben results in decreased expression of CYP19A1 protein
butylparaben results in increased expression of CYP19A1 mRNA
butylparaben affects the expression of CYP19A1 protein
butylparaben results in increased activity of CYP19A1 protein		 CTD PMID:23744433 PMID:25607892 PMID:26888303 PMID:27122241 PMID:30817981 NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601 		JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 decreases activity
multiple interactions		 ISO
EXP		 butylparaben results in decreased activity of CYP1A1 protein
[butylparaben co-treated with triclocarban] results in increased expression of CYP1A1 mRNA		 CTD PMID:23524099 PMID:27432241 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536 		JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 decreases activity ISO butylparaben results in decreased activity of CYP1A2 protein CTD PMID:27432241 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607 		JBrowse link
G CYP1B1 cytochrome P450 family 1 subfamily B member 1 multiple interactions
increases expression		 EXP butylparaben promotes the reaction [bisphenol A results in increased expression of CYP1B1 mRNA]
butylparaben results in increased expression of CYP1B1 mRNA		 CTD PMID:23524099 NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902 		JBrowse link
G CYP2C18 cytochrome P450 family 2 subfamily C member 18 decreases activity ISO butylparaben results in decreased activity of CYP2C11 protein CTD PMID:27432241 NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190 		JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 decreases activity ISO butylparaben results in decreased activity of CYP2E1 protein CTD PMID:27432241 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220 		JBrowse link
G DCC DCC netrin 1 receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DCC mRNA CTD PMID:25607892 NCBI chr18:52,340,197...53,535,899
Ensembl chr18:52,340,197...53,535,899 		JBrowse link
G DDIT3 DNA damage inducible transcript 3 increases expression EXP
ISO		 butylparaben results in increased expression of DDIT3 protein
butylparaben results in increased expression of DDIT3 mRNA		 CTD PMID:29319206 PMID:36277366 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737 		JBrowse link
G DIABLO diablo IAP-binding mitochondrial protein increases expression EXP butylparaben results in increased expression of DIABLO mRNA CTD PMID:24481588 NCBI chr12:122,207,662...122,227,456
Ensembl chr12:122,207,668...122,226,062 		JBrowse link
G DIO1 iodothyronine deiodinase 1 affects expression
decreases activity		 ISO butylparaben affects the expression of DIO1 mRNA
butylparaben results in decreased activity of DIO1 protein		 CTD PMID:32798586 NCBI chr 1:53,894,187...53,911,086
Ensembl chr 1:53,891,239...53,911,086 		JBrowse link
G DLG1 discs large MAGUK scaffold protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG1 mRNA CTD PMID:25607892 NCBI chr 3:197,042,560...197,299,321
Ensembl chr 3:197,042,560...197,299,330 		JBrowse link
G DLG4 discs large MAGUK scaffold protein 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DLG4 mRNA CTD PMID:25607892 NCBI chr17:7,187,187...7,220,050
Ensembl chr17:7,187,187...7,219,841 		JBrowse link
G DLGAP3 DLG associated protein 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of DLGAP3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLGAP3 mRNA CTD PMID:25607892 NCBI chr 1:34,865,436...34,929,650
Ensembl chr 1:34,865,436...34,929,650 		JBrowse link
G DNM1 dynamin 1 multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of DNM1 mRNA CTD PMID:34383603 NCBI chr 9:128,203,379...128,255,244
Ensembl chr 9:128,191,655...128,255,248 		JBrowse link
G DNMT3A DNA methyltransferase 3 alpha increases expression
multiple interactions		 ISO butylparaben results in increased expression of DNMT3A mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DNMT3A mRNA		 CTD PMID:25607892 PMID:26888303 NCBI chr 2:25,227,874...25,342,590
Ensembl chr 2:25,227,855...25,342,590 		JBrowse link
G DNMT3B DNA methyltransferase 3 beta increases expression ISO butylparaben results in increased expression of DNMT3B mRNA CTD PMID:26888303 NCBI chr20:32,762,385...32,809,356
Ensembl chr20:32,762,385...32,809,359 		JBrowse link
G DPP6 dipeptidyl peptidase like 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DPP6 mRNA CTD PMID:25607892 NCBI chr 7:153,748,133...154,894,285
Ensembl chr 7:153,748,133...154,894,285 		JBrowse link
G E2F1 E2F transcription factor 1 affects expression EXP butylparaben affects the expression of E2F1 mRNA CTD PMID:24481588 NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385 		JBrowse link
G E2F3 E2F transcription factor 3 affects expression EXP butylparaben affects the expression of E2F3 mRNA CTD PMID:24481588 NCBI chr 6:20,401,879...20,493,714
Ensembl chr 6:20,401,879...20,493,714 		JBrowse link
G EFNA4 ephrin A4 increases expression EXP butylparaben results in increased expression of EFNA4 mRNA CTD PMID:17121429 NCBI chr 1:155,063,740...155,069,553
Ensembl chr 1:155,063,737...155,069,553 		JBrowse link
G EGF epidermal growth factor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of EGF mRNA CTD PMID:25607892 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766 		JBrowse link
G ELP6 elongator acetyltransferase complex subunit 6 increases expression EXP butylparaben results in increased expression of ELP6 mRNA CTD PMID:17121429 NCBI chr 3:47,495,640...47,513,712
Ensembl chr 3:47,495,640...47,513,712 		JBrowse link
G ERBB2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426 		JBrowse link
G ERBB3 erb-b2 receptor tyrosine kinase 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA CTD PMID:25607892 NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505 		JBrowse link
G ERBB4 erb-b2 receptor tyrosine kinase 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA CTD PMID:25607892 NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841 		JBrowse link
G ERCC2 ERCC excision repair 2, TFIIH core complex helicase subunit increases expression EXP butylparaben results in increased expression of ERCC2 mRNA CTD PMID:17121429 NCBI chr19:45,349,837...45,370,573
Ensembl chr19:45,349,837...45,370,918 		JBrowse link
G ERN1 endoplasmic reticulum to nucleus signaling 1 increases expression EXP butylparaben results in increased expression of ERN1 protein CTD PMID:29319206 NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819 		JBrowse link
G ESR1 estrogen receptor 1 affects binding
multiple interactions
increases expression
decreases activity
decreases expression
decreases methylation
increases activity		 EXP
ISO		 butylparaben binds to ESR1 protein; butylparaben metabolite binds to ESR1 protein
[Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of ESR1 mRNA; butylparaben inhibits the reaction [Estradiol binds to ESR1 protein]; Fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 mRNA]; Fulvestrant inhibits the reaction [butylparaben results in decreased expression of ESR1 protein]
butylparaben results in increased expression of ESR1 mRNA; butylparaben results in increased expression of ESR1 protein
butylparaben results in decreased activity of ESR1 protein
butylparaben results in decreased expression of ESR1 mRNA; butylparaben results in decreased expression of ESR1 protein
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; butylparaben binds to and results in increased activity of ESR1 protein; Fulvestrant inhibits the reaction [butylparaben results in increased activity of ESR1 protein]
butylparaben results in decreased methylation of ESR1 promoter		 CTD PMID:11193391 PMID:15204698 PMID:19063592 PMID:19654335 PMID:20074635 More... NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619 		JBrowse link
G ESR2 estrogen receptor 2 affects binding
decreases expression
increases expression
multiple interactions		 EXP
ISO		 butylparaben binds to ESR2 protein
butylparaben results in decreased expression of ESR2 mRNA
butylparaben results in increased expression of ESR2 mRNA
butylparaben binds to and results in increased activity of ESR2 protein
butylparaben results in increased expression of ESR2 mRNA; butylparaben results in increased expression of ESR2 protein		 CTD PMID:11193391 PMID:18648085 PMID:20132880 PMID:23567241 PMID:25128701 More... NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112 		JBrowse link
G ESRRG estrogen related receptor gamma multiple interactions EXP butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] CTD PMID:23583298 NCBI chr 1:216,503,246...217,137,702
Ensembl chr 1:216,503,246...217,137,755 		JBrowse link
G FAAH fatty acid amide hydrolase decreases activity ISO
EXP		 butylparaben results in decreased activity of FAAH protein CTD PMID:27659731 NCBI chr 1:46,394,317...46,413,845
Ensembl chr 1:46,394,317...46,413,848 		JBrowse link
G FABP4 fatty acid binding protein 4 increases expression
multiple interactions		 EXP
ISO		 butylparaben results in increased expression of FABP4 mRNA
butylparaben promotes the reaction [Dexamethasone results in increased expression of FABP4 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]		 CTD PMID:22956630 PMID:24155963 PMID:27659731 PMID:28527915 NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236 		JBrowse link
G FASN fatty acid synthase increases expression
multiple interactions		 ISO
EXP		 butylparaben results in increased expression of FASN mRNA
butylparaben promotes the reaction [Dexamethasone results in increased expression of FASN mRNA]		 CTD PMID:22956630 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294 		JBrowse link
G FBXL9P F-box and leucine rich repeat protein, pseudogene increases expression EXP butylparaben results in increased expression of FBXL9P mRNA CTD PMID:17121429 NCBI chr16:67,207,139...67,227,025
Ensembl chr16:67,207,139...67,227,048
Ensembl chr16:67,207,139...67,227,048 		JBrowse link
G FGFR1 fibroblast growth factor receptor 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR1 mRNA CTD PMID:25607892 NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834 		JBrowse link
G FGFR2 fibroblast growth factor receptor 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA CTD PMID:25607892 NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458 		JBrowse link
G FSHB follicle stimulating hormone subunit beta decreases expression
decreases secretion		 ISO butylparaben results in decreased expression of FSHB protein
butylparaben results in decreased secretion of FSHB protein		 CTD PMID:27444704 PMID:29350491 NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261 		JBrowse link
G FUS FUS RNA binding protein increases expression EXP butylparaben results in increased expression of FUS mRNA CTD PMID:17121429 NCBI chr16:31,180,110...31,194,871
Ensembl chr16:31,180,138...31,191,605 		JBrowse link
G FYN FYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of FYN mRNA CTD PMID:25607892 NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452 		JBrowse link
G GABRA4 gamma-aminobutyric acid type A receptor subunit alpha4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRA4 mRNA CTD PMID:25607892 NCBI chr 4:46,918,900...46,993,581
Ensembl chr 4:46,918,900...46,993,581 		JBrowse link
G GABRB1 gamma-aminobutyric acid type A receptor subunit beta1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRB1 mRNA CTD PMID:25607892 NCBI chr 4:46,993,647...47,426,447
Ensembl chr 4:46,993,723...47,426,447 		JBrowse link
G GLS glutaminase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GLS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GLS mRNA CTD PMID:25607892 NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552 		JBrowse link
G GPER1 G protein-coupled estrogen receptor 1 increases expression EXP butylparaben results in increased expression of GPER1 mRNA; butylparaben results in increased expression of GPER1 protein CTD PMID:17121429 PMID:26253279 NCBI chr 7:1,087,118...1,093,810
Ensembl chr 7:1,082,208...1,093,815 		JBrowse link
G GREB1 growth regulating estrogen receptor binding 1 increases expression
multiple interactions		 EXP butylparaben metabolite results in increased expression of GREB1 mRNA; butylparaben results in increased expression of GREB1 mRNA
Fulvestrant inhibits the reaction [butylparaben metabolite results in increased expression of GREB1 mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of GREB1 mRNA]		 CTD PMID:17121429 PMID:29945225 NCBI chr 2:11,482,888...11,642,788
Ensembl chr 2:11,482,341...11,642,788 		JBrowse link
G GRIA2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA CTD PMID:25607892 NCBI chr 4:157,220,120...157,366,075
Ensembl chr 4:157,204,182...157,387,146 		JBrowse link
G GRIA4 glutamate ionotropic receptor AMPA type subunit 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIA4 mRNA CTD PMID:25607892 NCBI chr11:105,609,616...105,982,090
Ensembl chr11:105,609,535...105,982,090 		JBrowse link
G GRID2 glutamate ionotropic receptor delta type subunit 2 multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of GRID2 mRNA CTD PMID:34383603 NCBI chr 4:92,303,966...93,810,456
Ensembl chr 4:92,303,966...93,810,157 		JBrowse link
G GRIK2 glutamate ionotropic receptor kainate type subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA CTD PMID:25607892 NCBI chr 6:101,393,708...102,070,083
Ensembl chr 6:100,962,701...102,081,622 		JBrowse link
G GRIK4 glutamate ionotropic receptor kainate type subunit 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA CTD PMID:25607892 NCBI chr11:120,511,748...120,988,906
Ensembl chr11:120,511,746...120,988,906 		JBrowse link
G GRIK5 glutamate ionotropic receptor kainate type subunit 5 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK5 mRNA CTD PMID:25607892 NCBI chr19:41,998,324...42,070,206
Ensembl chr19:41,998,321...42,070,206 		JBrowse link
G GRIN1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of GRIN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN1 mRNA CTD PMID:25607892 NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756 		JBrowse link
G GRIN2B glutamate ionotropic receptor NMDA type subunit 2B multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2B mRNA CTD PMID:25607892 NCBI chr12:13,537,337...13,982,134
Ensembl chr12:13,437,942...13,982,002 		JBrowse link
G GRIN2C glutamate ionotropic receptor NMDA type subunit 2C multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2C mRNA CTD PMID:25607892 NCBI chr17:74,842,023...74,861,532
Ensembl chr17:74,842,023...74,861,504 		JBrowse link
G GRIN2D glutamate ionotropic receptor NMDA type subunit 2D multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA; [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA CTD PMID:25607892 PMID:34383603 NCBI chr19:48,393,668...48,444,931
Ensembl chr19:48,393,668...48,444,931 		JBrowse link
G GRIN3A glutamate ionotropic receptor NMDA type subunit 3A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN3A mRNA CTD PMID:25607892 NCBI chr 9:101,569,352...101,738,647
Ensembl chr 9:101,569,352...101,738,647 		JBrowse link
G GRIP1 glutamate receptor interacting protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIP1 mRNA CTD PMID:25607892 NCBI chr12:66,347,431...67,069,338
Ensembl chr12:66,347,431...67,069,162 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta decreases phosphorylation EXP butylparaben results in decreased phosphorylation of GSK3B protein CTD PMID:29319206 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G HES6 hes family bHLH transcription factor 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HES6 mRNA CTD PMID:25607892 NCBI chr 2:238,238,267...238,240,038
Ensembl chr 2:238,238,267...238,240,662 		JBrowse link
G HEXB hexosaminidase subunit beta multiple interactions ISO zinc chloride inhibits the reaction [butylparaben results in increased secretion of HEXB protein] CTD PMID:15272608 NCBI chr 5:74,640,023...74,721,288
Ensembl chr 5:74,640,023...74,722,647 		JBrowse link
G HPS6 HPS6 biogenesis of lysosomal organelles complex 2 subunit 3 increases expression EXP butylparaben results in increased expression of HPS6 mRNA CTD PMID:17121429 NCBI chr10:102,065,349...102,068,036
Ensembl chr10:102,065,349...102,068,036 		JBrowse link
G HR HR lysine demethylase and nuclear receptor corepressor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HR mRNA CTD PMID:25607892 NCBI chr 8:22,114,419...22,131,052
Ensembl chr 8:22,114,419...22,133,384 		JBrowse link
G HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HSD17B10 mRNA CTD PMID:25607892 NCBI chr  X:53,431,258...53,434,376
Ensembl chr  X:53,431,258...53,434,370 		JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of HSD17B8 mRNA CTD PMID:25607892 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831 		JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP
ISO		 butylparaben results in increased expression of HSPA5 protein
butylparaben results in increased expression of HSPA5 mRNA		 CTD PMID:29319206 PMID:36277366 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382 		JBrowse link
G HSPB8 heat shock protein family B (small) member 8 increases expression EXP butylparaben results in increased expression of HSPB8 mRNA CTD PMID:23524099 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855 		JBrowse link
G IGDCC3 immunoglobulin superfamily DCC subclass member 3 increases expression EXP butylparaben results in increased expression of IGDCC3 mRNA CTD PMID:17121429 NCBI chr15:65,327,127...65,378,002
Ensembl chr15:65,327,127...65,378,002 		JBrowse link
G IGF1R insulin like growth factor 1 receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of IGF1R mRNA CTD PMID:25607892 NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530 		JBrowse link
G IGF2R insulin like growth factor 2 receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of IGF2R mRNA CTD PMID:25607892 NCBI chr 6:159,969,082...160,111,504
Ensembl chr 6:159,969,082...160,113,507 		JBrowse link
G IL17RB interleukin 17 receptor B increases expression EXP butylparaben results in increased expression of IL17RB mRNA CTD PMID:17121429 NCBI chr 3:53,846,568...53,865,794
Ensembl chr 3:53,846,568...53,865,794 		JBrowse link
G IL1RAPL1 interleukin 1 receptor accessory protein like 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of IL1RAPL1 mRNA CTD PMID:25607892 NCBI chr  X:28,587,446...29,956,718
Ensembl chr  X:28,587,446...29,956,718 		JBrowse link
G INCENP inner centromere protein increases expression EXP butylparaben results in increased expression of INCENP mRNA CTD PMID:17121429 NCBI chr11:62,124,011...62,153,169
Ensembl chr11:62,123,998...62,153,169 		JBrowse link
G INS insulin multiple interactions EXP butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein] CTD PMID:31016361 NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221 		JBrowse link
G JAG1 jagged canonical Notch ligand 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of JAG1 mRNA CTD PMID:25607892 NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999 		JBrowse link
G KCNC1 potassium voltage-gated channel subfamily C member 1 increases expression EXP butylparaben results in increased expression of KCNC1 mRNA CTD PMID:17121429 NCBI chr11:17,734,781...17,783,057
Ensembl chr11:17,734,774...17,856,804 		JBrowse link
G KCNF1 potassium voltage-gated channel modifier subfamily F member 1 increases expression EXP butylparaben results in increased expression of KCNF1 mRNA CTD PMID:17121429 NCBI chr 2:10,911,934...10,914,225
Ensembl chr 2:10,911,934...10,914,225 		JBrowse link
G KISS1 KiSS-1 metastasis suppressor multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of KISS1 mRNA CTD PMID:34383603 NCBI chr 1:204,190,341...204,196,491
Ensembl chr 1:204,190,341...204,196,491 		JBrowse link
G KMT2D lysine methyltransferase 2D increases expression EXP butylparaben results in increased expression of KMT2D mRNA CTD PMID:17121429 NCBI chr12:49,018,978...49,060,794
Ensembl chr12:49,018,975...49,060,794 		JBrowse link
G KRT8 keratin 8 increases expression EXP butylparaben results in increased expression of KRT8 mRNA CTD PMID:17121429 NCBI chr12:52,897,191...52,949,860
Ensembl chr12:52,897,187...52,949,954 		JBrowse link
G KRT82 keratin 82 increases expression EXP butylparaben results in increased expression of KRT82 mRNA CTD PMID:17121429 NCBI chr12:52,393,931...52,406,335
Ensembl chr12:52,393,931...52,406,335 		JBrowse link
G LEF1 lymphoid enhancer binding factor 1 increases expression EXP butylparaben results in increased expression of LEF1 mRNA CTD PMID:17121429 NCBI chr 4:108,047,548...108,168,932
Ensembl chr 4:108,047,545...108,168,956 		JBrowse link
G LEP leptin decreases expression
increases expression		 EXP
ISO		 butylparaben results in decreased expression of LEP mRNA
butylparaben results in increased expression of LEP mRNA		 CTD PMID:22956630 NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629 		JBrowse link
G LHB luteinizing hormone subunit beta multiple interactions
decreases expression
decreases secretion		 ISO butylparaben promotes the reaction [Triclosan results in decreased secretion of LHB protein]; Triclosan promotes the reaction [butylparaben results in decreased secretion of LHB protein]
butylparaben results in decreased expression of LHB protein		 CTD PMID:27444704 PMID:29350491 NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091 		JBrowse link
G LIN7A lin-7 homolog A, crumbs cell polarity complex component multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of LIN7A mRNA CTD PMID:25607892 NCBI chr12:80,792,520...80,937,934
Ensembl chr12:80,792,520...80,937,934 		JBrowse link
G LMOD1 leiomodin 1 increases expression EXP butylparaben results in increased expression of LMOD1 mRNA CTD PMID:17121429 NCBI chr 1:201,896,456...201,946,548
Ensembl chr 1:201,896,456...201,946,548 		JBrowse link
G LPIN1 lipin 1 increases expression
multiple interactions		 ISO butylparaben results in increased expression of LPIN1 mRNA
[Dexamethasone co-treated with butylparaben] results in increased expression of LPIN1 mRNA; NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA]		 CTD PMID:22956630 NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409 		JBrowse link
G MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MAGI2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MAGI2 mRNA CTD PMID:25607892 NCBI chr 7:78,017,055...79,453,667
Ensembl chr 7:78,017,055...79,453,667 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation EXP butylparaben results in increased phosphorylation of MAPK1 protein CTD PMID:26253279 PMID:29319206 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases phosphorylation EXP butylparaben results in increased phosphorylation of MAPK3 protein CTD PMID:26253279 PMID:29319206 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MASP1 MBL associated serine protease 1 increases expression EXP butylparaben results in increased expression of MASP1 mRNA CTD PMID:17121429 NCBI chr 3:187,217,282...187,291,737
Ensembl chr 3:187,217,282...187,291,980 		JBrowse link
G MDGA2 MAM domain containing glycosylphosphatidylinositol anchor 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MDGA2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MDGA2 mRNA CTD PMID:25607892 NCBI chr14:46,839,623...47,675,605
Ensembl chr14:46,840,092...47,675,605 		JBrowse link
G MET MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MET mRNA CTD PMID:25607892 NCBI chr 7:116,672,196...116,798,377
Ensembl chr 7:116,672,196...116,798,377 		JBrowse link
G MMP3 matrix metallopeptidase 3 multiple interactions ISO [enzacamene co-treated with octylmethoxycinnamate co-treated with bisphenol A co-treated with butylparaben] results in increased expression of MMP3 mRNA CTD PMID:25305543 NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609 		JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions		 EXP butylparaben results in increased expression of MYC mRNA
[butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; [NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein; butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]; NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]		 CTD PMID:26502914 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951 		JBrowse link
G NCOA2 nuclear receptor coactivator 2 multiple interactions EXP butylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] CTD PMID:23583298 NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808 		JBrowse link
G NF1 neurofibromin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NF1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NF1 mRNA CTD PMID:25607892 NCBI chr17:31,094,927...31,377,677
Ensembl chr17:31,094,927...31,382,116 		JBrowse link
G NLGN1 neuroligin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA CTD PMID:25607892 NCBI chr 3:173,395,952...174,294,372
Ensembl chr 3:173,396,284...174,294,372 		JBrowse link
G NOTCH2 notch receptor 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH2 mRNA CTD PMID:25607892 NCBI chr 1:119,911,553...120,069,662
Ensembl chr 1:119,911,553...120,100,779 		JBrowse link
G NOTCH4 notch receptor 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH4 mRNA CTD PMID:25607892 NCBI chr 6:32,194,843...32,224,067
Ensembl chr 6:32,194,843...32,224,067 		JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases expression ISO
EXP		 butylparaben results in increased expression of NR1I2 mRNA CTD PMID:31472229 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487 		JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases expression ISO butylparaben results in increased expression of NR1I3 mRNA CTD PMID:31472229 NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244 		JBrowse link
G NR3C1 nuclear receptor subfamily 3 group C member 1 multiple interactions
increases response to substance
increases activity		 ISO
EXP		 NR3C1 mutant form inhibits the reaction [butylparaben results in increased expression of LPIN1 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
[Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of NR3C1 mRNA
[butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin co-treated with propylparaben] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben co-treated with tetramethrin] results in increased activity of NR3C1 protein; [Diethylhexyl Phthalate co-treated with butylparaben] results in increased activity of NR3C1 protein
NR3C1 protein results in increased susceptibility to butylparaben
butylparaben results in increased activity of NR3C1 protein		 CTD PMID:22956630 PMID:25448277 PMID:28527915 PMID:34383603 NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512 		JBrowse link
G NR3C2 nuclear receptor subfamily 3 group C member 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA CTD PMID:25607892 NCBI chr 4:148,078,764...148,445,508
Ensembl chr 4:148,078,762...148,444,698 		JBrowse link
G NR5A1 nuclear receptor subfamily 5 group A member 1 decreases expression ISO butylparaben results in decreased expression of NR5A1 mRNA CTD PMID:27122241 NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420 		JBrowse link
G NRCAM neuronal cell adhesion molecule multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRCAM mRNA CTD PMID:25607892 NCBI chr 7:108,147,649...108,456,720
Ensembl chr 7:108,147,623...108,456,717 		JBrowse link
G NRG1 neuregulin 1 multiple interactions EXP
ISO		 [butylparaben co-treated with NRG1 protein] promotes the reaction [ESR1 protein binds to MYC enhancer]; [NRG1 protein co-treated with butylparaben] results in increased expression of MYC protein; butylparaben promotes the reaction [NRG1 protein results in increased expression of MYC mRNA]; NRG1 protein promotes the reaction [butylparaben results in increased expression of MYC mRNA]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NRG1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRG1 mRNA		 CTD PMID:25607892 PMID:26502914 NCBI chr 8:31,639,245...32,774,046
Ensembl chr 8:31,639,222...32,855,666 		JBrowse link
G NRXN1 neurexin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN1 mRNA CTD PMID:25607892 NCBI chr 2:49,918,503...51,032,132
Ensembl chr 2:49,918,503...51,225,575 		JBrowse link
G NRXN2 neurexin 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRXN2 mRNA CTD PMID:25607892 NCBI chr11:64,606,174...64,723,197
Ensembl chr11:64,606,174...64,723,197 		JBrowse link
G NTRK1 neurotrophic receptor tyrosine kinase 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK1 mRNA CTD PMID:25607892 NCBI chr 1:156,815,750...156,881,850
Ensembl chr 1:156,815,636...156,881,850 		JBrowse link
G NTRK2 neurotrophic receptor tyrosine kinase 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NTRK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK2 mRNA CTD PMID:25607892 NCBI chr 9:84,668,522...85,027,054
Ensembl chr 9:84,668,375...85,095,751 		JBrowse link
G NTRK3 neurotrophic receptor tyrosine kinase 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK3 mRNA CTD PMID:25607892 NCBI chr15:87,859,751...88,256,739
Ensembl chr15:87,859,751...88,256,791 		JBrowse link
G NXPH3 neurexophilin 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NXPH3 mRNA CTD PMID:25607892 NCBI chr17:49,575,871...49,583,827
Ensembl chr17:49,575,871...49,583,827 		JBrowse link
G OTOF otoferlin increases expression EXP butylparaben results in increased expression of OTOF mRNA CTD PMID:17121429 NCBI chr 2:26,457,203...26,558,756
Ensembl chr 2:26,457,203...26,558,756 		JBrowse link
G OXT oxytocin/neurophysin I prepropeptide multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of OXT mRNA CTD PMID:34383603 NCBI chr20:3,071,620...3,072,517
Ensembl chr20:3,071,620...3,072,517 		JBrowse link
G PCDHA3 protocadherin alpha 3 increases expression EXP butylparaben results in increased expression of PCDHA3 mRNA CTD PMID:17121429 NCBI chr 5:140,801,057...141,012,347
Ensembl chr 5:140,801,028...141,012,347 		JBrowse link
G PCDHGC3 protocadherin gamma subfamily C, 3 increases expression EXP butylparaben results in increased expression of PCDHGC3 mRNA CTD PMID:17121429 NCBI chr 5:141,475,966...141,512,975
Ensembl chr 5:141,475,947...141,512,977 		JBrowse link
G PEX14 peroxisomal biogenesis factor 14 increases expression EXP butylparaben results in increased expression of PEX14 mRNA CTD PMID:17121429 NCBI chr 1:10,474,950...10,630,758
Ensembl chr 1:10,472,288...10,630,758 		JBrowse link
G PGR progesterone receptor increases expression
multiple interactions		 ISO
EXP		 butylparaben results in increased expression of PGR mRNA; butylparaben results in increased expression of PGR protein
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PGR mRNA; Fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of PGR protein]
Silver inhibits the reaction [butylparaben results in increased expression of PGR mRNA]		 CTD PMID:17121429 PMID:19654335 PMID:23524099 PMID:25128701 PMID:25607892 More... NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813 		JBrowse link
G PI4KA phosphatidylinositol 4-kinase alpha increases expression EXP butylparaben results in increased expression of PI4KA mRNA CTD PMID:17121429 NCBI chr22:20,707,691...20,858,811
Ensembl chr22:20,707,691...20,859,417 		JBrowse link
G PLIN1 perilipin 1 increases expression
multiple interactions		 ISO butylparaben results in increased expression of PLIN1 mRNA
NR3C1 protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]		 CTD PMID:22956630 PMID:28527915 NCBI chr15:89,664,367...89,679,367
Ensembl chr15:89,664,367...89,679,427 		JBrowse link
G POMC proopiomelanocortin multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] affects the expression of POMC mRNA CTD PMID:34383603 NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903 		JBrowse link
G PPARA peroxisome proliferator activated receptor alpha increases expression ISO butylparaben results in increased expression of PPARA mRNA CTD PMID:31472229 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions
increases activity
increases expression
increases response to substance		 ISO
EXP		 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of PPARG mRNA]; Mifepristone inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG mutant form inhibits the reaction [butylparaben results in increased expression of PLIN1 mRNA]; PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA]; PPARG protein promotes the reaction [butylparaben binds to and results in increased activity of PPARG protein]; PPARG protein promotes the reaction [butylparaben results in decreased expression of ALPL mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of CEBPA mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of FABP4 mRNA]; PPARG protein promotes the reaction [butylparaben results in increased expression of PLIN1 mRNA]
butylparaben results in increased activity of PPARG protein
PPARG protein results in increased susceptibility to butylparaben		 CTD PMID:22956630 PMID:24155963 PMID:27659731 PMID:28527915 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PPP1R1B protein phosphatase 1 regulatory inhibitor subunit 1B multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of PPP1R1B mRNA CTD PMID:34383603 NCBI chr17:39,626,707...39,636,624
Ensembl chr17:39,626,740...39,636,626 		JBrowse link
G PRKN parkin RBR E3 ubiquitin protein ligase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA CTD PMID:25607892 NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775 		JBrowse link
G PRLR prolactin receptor increases expression EXP butylparaben results in increased expression of PRLR mRNA CTD PMID:17121429 NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487 		JBrowse link
G PYROXD2 pyridine nucleotide-disulphide oxidoreductase domain 2 decreases expression EXP butylparaben results in decreased expression of PYROXD2 mRNA CTD PMID:17121429 NCBI chr10:98,383,568...98,415,182
Ensembl chr10:98,383,565...98,415,182 		JBrowse link
G RELN reelin multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of RELN mRNA CTD PMID:25607892 NCBI chr 7:103,471,789...103,989,658
Ensembl chr 7:103,471,381...103,989,658 		JBrowse link
G ROBO1 roundabout guidance receptor 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ROBO1 mRNA CTD PMID:25607892 NCBI chr 3:78,597,239...79,767,998
Ensembl chr 3:78,597,239...79,767,998 		JBrowse link
G RPS6 ribosomal protein S6 multiple interactions
decreases phosphorylation		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butylparaben results in decreased phosphorylation of RPS6 protein] CTD PMID:29319206 NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236 		JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions		 EXP butylparaben results in decreased phosphorylation of RPS6KB1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butylparaben results in decreased phosphorylation of RPS6KB1 protein]; U 0126 inhibits the reaction [butylparaben results in decreased phosphorylation of RPS6KB1 protein]		 CTD PMID:29319206 NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574 		JBrowse link
G RUNX2 RUNX family transcription factor 2 decreases expression ISO butylparaben results in decreased expression of RUNX2 mRNA CTD PMID:28527915 NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349 		JBrowse link
G S100G S100 calcium binding protein G multiple interactions
increases expression		 ISO Fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G mRNA]; Fulvestrant inhibits the reaction [butylparaben results in increased expression of S100G protein]
butylparaben results in increased expression of S100G mRNA; butylparaben results in increased expression of S100G protein		 CTD PMID:19654335 NCBI chr  X:16,650,158...16,654,670
Ensembl chr  X:16,650,158...16,654,670 		JBrowse link
G SHANK1 SH3 and multiple ankyrin repeat domains 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SHANK1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK1 mRNA CTD PMID:25607892 NCBI chr19:50,659,255...50,719,802
Ensembl chr19:50,659,255...50,719,802 		JBrowse link
G SHANK2 SH3 and multiple ankyrin repeat domains 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA CTD PMID:25607892 NCBI chr11:70,467,854...71,253,228
Ensembl chr11:70,467,854...71,252,577 		JBrowse link
G SHANK3 SH3 and multiple ankyrin repeat domains 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA CTD PMID:25607892 NCBI chr22:50,672,823...50,733,212
Ensembl chr22:50,674,415...50,733,212 		JBrowse link
G SIAH2 siah E3 ubiquitin protein ligase 2 decreases expression EXP butylparaben results in decreased expression of SIAH2 mRNA CTD PMID:17121429 NCBI chr 3:150,741,125...150,763,169
Ensembl chr 3:150,741,125...150,763,477 		JBrowse link
G SLC17A7 solute carrier family 17 member 7 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC17A7 mRNA CTD PMID:25607892 NCBI chr19:49,429,401...49,441,527
Ensembl chr19:49,429,401...49,442,360 		JBrowse link
G SLC1A1 solute carrier family 1 member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A1 mRNA CTD PMID:25607892 NCBI chr 9:4,490,468...4,587,469
Ensembl chr 9:4,490,468...4,587,469 		JBrowse link
G SLC1A2 solute carrier family 1 member 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A2 mRNA CTD PMID:25607892 NCBI chr11:35,251,205...35,420,507
Ensembl chr11:35,251,205...35,420,063 		JBrowse link
G SLC1A3 solute carrier family 1 member 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A3 mRNA CTD PMID:25607892 NCBI chr 5:36,606,606...36,688,334
Ensembl chr 5:36,596,588...36,688,334 		JBrowse link
G SLC1A6 solute carrier family 1 member 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A6 mRNA CTD PMID:25607892 NCBI chr19:14,950,033...15,010,643
Ensembl chr19:14,950,033...15,022,990 		JBrowse link
G SLC22A2 solute carrier family 22 member 2 multiple interactions EXP butylparaben inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638 		JBrowse link
G SLIT1 slit guidance ligand 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SLIT1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLIT1 mRNA CTD PMID:25607892 NCBI chr10:96,998,038...97,185,959
Ensembl chr10:96,998,038...97,185,959 		JBrowse link
G SMC1A structural maintenance of chromosomes 1A increases expression EXP butylparaben results in increased expression of SMC1A mRNA CTD PMID:17121429 NCBI chr  X:53,374,149...53,422,728
Ensembl chr  X:53,374,149...53,422,728 		JBrowse link
G SOX15 SRY-box transcription factor 15 increases expression EXP butylparaben results in increased expression of SOX15 mRNA CTD PMID:17121429 NCBI chr17:7,588,178...7,590,094
Ensembl chr17:7,588,178...7,590,094 		JBrowse link
G SPP1 secreted phosphoprotein 1 decreases expression
multiple interactions		 ISO butylparaben results in decreased expression of SPP1 mRNA
NR3C1 protein promotes the reaction [butylparaben results in decreased expression of SPP1 mRNA]; PPARG protein inhibits the reaction [butylparaben results in decreased expression of SPP1 mRNA]		 CTD PMID:28527915 NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532 		JBrowse link
G SPTBN2 spectrin beta, non-erythrocytic 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SPTBN2 mRNA CTD PMID:25607892 NCBI chr11:66,682,497...66,744,682
Ensembl chr11:66,682,497...66,744,670 		JBrowse link
G STAR steroidogenic acute regulatory protein decreases expression ISO butylparaben results in decreased expression of STAR mRNA; butylparaben results in decreased expression of STAR protein CTD PMID:18648085 PMID:26888303 NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992 		JBrowse link
G STMN2 stathmin 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STMN2 mRNA CTD PMID:25607892 NCBI chr 8:79,611,117...79,666,158
Ensembl chr 8:79,611,117...79,666,158 		JBrowse link
G STS steroid sulfatase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of STS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of STS mRNA CTD PMID:25607892 NCBI chr  X:7,147,290...7,354,641
Ensembl chr  X:7,147,237...7,804,358 		JBrowse link
G STX1B syntaxin 1B multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STX1B mRNA CTD PMID:25607892 NCBI chr16:30,989,256...31,010,638
Ensembl chr16:30,989,256...31,010,638 		JBrowse link
G STXBP1 syntaxin binding protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of STXBP1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STXBP1 mRNA CTD PMID:25607892 NCBI chr 9:127,611,912...127,696,029
Ensembl chr 9:127,579,370...127,696,027 		JBrowse link
G SULT1E1 sulfotransferase family 1E member 1 decreases expression ISO butylparaben results in decreased expression of SULT1E1 mRNA; butylparaben results in decreased expression of SULT1E1 protein CTD PMID:26888303 NCBI chr 4:69,821,122...69,860,145
Ensembl chr 4:69,841,212...69,860,145 		JBrowse link
G SYNGAP1 synaptic Ras GTPase activating protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SYNGAP1 mRNA CTD PMID:25607892 NCBI chr 6:33,418,167...33,453,689
Ensembl chr 6:33,419,661...33,453,689 		JBrowse link
G SYP synaptophysin multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SYP mRNA CTD PMID:25607892 NCBI chr  X:49,187,815...49,200,193
Ensembl chr  X:49,187,815...49,200,218 		JBrowse link
G SYT6 synaptotagmin 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SYT6 mRNA CTD PMID:25607892 NCBI chr 1:114,089,292...114,153,869
Ensembl chr 1:114,089,291...114,153,880 		JBrowse link
G TCEA3 transcription elongation factor A3 increases expression EXP butylparaben results in increased expression of TCEA3 mRNA CTD PMID:17121429 NCBI chr 1:23,380,909...23,424,748
Ensembl chr 1:23,380,909...23,424,748 		JBrowse link
G TFAP2B transcription factor AP-2 beta increases expression EXP butylparaben results in increased expression of TFAP2B mRNA CTD PMID:37690743 NCBI chr 6:50,818,355...50,847,619
Ensembl chr 6:50,818,723...50,847,619 		JBrowse link
G TFF1 trefoil factor 1 increases expression
multiple interactions		 EXP butylparaben results in increased expression of TFF1 mRNA
Fulvestrant inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA]; Silver inhibits the reaction [butylparaben results in increased expression of TFF1 mRNA]		 CTD PMID:16797915 PMID:17121429 PMID:22562034 PMID:23524099 PMID:29074358 NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535 		JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TGFB1 mRNA CTD PMID:25607892 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TH tyrosine hydroxylase multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of TH mRNA CTD PMID:34383603 NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815 		JBrowse link
G TNFRSF10A TNF receptor superfamily member 10a increases expression EXP butylparaben results in increased expression of TNFRSF10A mRNA CTD PMID:24481588 NCBI chr 8:23,190,452...23,225,102
Ensembl chr 8:23,190,452...23,225,102 		JBrowse link
G TNFRSF11B TNF receptor superfamily member 11b multiple interactions EXP butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein] CTD PMID:31016361 NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885 		JBrowse link
G TNFRSF1A TNF receptor superfamily member 1A increases expression EXP butylparaben results in increased expression of TNFRSF1A mRNA CTD PMID:24481588 NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114 		JBrowse link
G TNFRSF21 TNF receptor superfamily member 21 decreases expression EXP butylparaben results in decreased expression of TNFRSF21 mRNA CTD PMID:24481588 NCBI chr 6:47,231,532...47,309,905
Ensembl chr 6:47,231,532...47,309,905 		JBrowse link
G TPO thyroid peroxidase increases expression
increases activity		 ISO butylparaben results in increased expression of TPO mRNA
butylparaben results in increased activity of TPO protein		 CTD PMID:32798586 NCBI chr 2:1,374,047...1,543,673
Ensembl chr 2:1,374,066...1,543,711 		JBrowse link
G TSC2 TSC complex subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of TSC2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of TSC2 mRNA CTD PMID:25607892 NCBI chr16:2,047,985...2,089,491
Ensembl chr16:2,047,967...2,089,491 		JBrowse link
G TSHB thyroid stimulating hormone subunit beta increases expression ISO butylparaben results in increased expression of TSHB protein CTD PMID:32798586 NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302 		JBrowse link
G TSNAX translin associated factor X multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TSNAX mRNA CTD PMID:25607892 NCBI chr 1:231,528,669...231,566,524
Ensembl chr 1:231,528,541...231,566,524 		JBrowse link
G TSPO translocator protein decreases expression ISO butylparaben results in decreased expression of TSPO mRNA CTD PMID:18648085 NCBI chr22:43,151,559...43,163,242
Ensembl chr22:43,151,547...43,163,242 		JBrowse link
G UBD ubiquitin D decreases expression EXP butylparaben results in decreased expression of UBD mRNA CTD PMID:17121429 NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732 		JBrowse link
G UGT2B15 UDP glucuronosyltransferase family 2 member B15 increases expression EXP butylparaben results in increased expression of UGT2B15 mRNA CTD PMID:23524099 NCBI chr 4:68,646,597...68,670,652
Ensembl chr 4:68,646,597...68,670,652 		JBrowse link
G UNC5A unc-5 netrin receptor A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5A mRNA CTD PMID:25607892 NCBI chr 5:176,810,559...176,880,898
Ensembl chr 5:176,810,519...176,880,898 		JBrowse link
G UNC5B unc-5 netrin receptor B multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5B mRNA CTD PMID:25607892 NCBI chr10:71,212,570...71,302,864
Ensembl chr10:71,212,570...71,302,864 		JBrowse link
G UNC5C unc-5 netrin receptor C multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of UNC5C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of UNC5C mRNA CTD PMID:25607892 NCBI chr 4:95,162,504...95,548,973
Ensembl chr 4:95,162,504...95,549,206 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of VEGFA mRNA CTD PMID:25607892 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VILL villin like increases expression EXP butylparaben results in increased expression of VILL mRNA CTD PMID:17121429 NCBI chr 3:37,987,978...38,007,185
Ensembl chr 3:37,988,059...38,007,188 		JBrowse link
G VLDLR very low density lipoprotein receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of VLDLR mRNA CTD PMID:25607892 NCBI chr 9:2,621,787...2,660,056
Ensembl chr 9:2,621,182...2,660,056 		JBrowse link
G WNK4 WNK lysine deficient protein kinase 4 increases expression EXP butylparaben results in increased expression of WNK4 mRNA CTD PMID:17121429 NCBI chr17:42,780,610...42,797,066
Ensembl chr17:42,780,610...42,797,066 		JBrowse link
G XBP1 X-box binding protein 1 increases expression ISO butylparaben results in increased expression of XBP1 mRNA; butylparaben results in increased expression of XBP1 mRNA alternative form CTD PMID:36277366 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597 		JBrowse link
G ZNF397 zinc finger protein 397 increases expression EXP butylparaben results in increased expression of ZNF397 mRNA CTD PMID:17121429 NCBI chr18:35,241,034...35,259,227
Ensembl chr18:35,241,030...35,267,133 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26041
    chemical entity 26020
      atom 26016
        nonmetal atom 25505
          carbon atom 25399
            organic molecular entity 25399
              Butylparaben 256
Path 2
Term Annotations click to browse term
  CHEBI ontology 26041
    subatomic particle 26016
      composite particle 26016
        hadron 26016
          baryon 26016
            nucleon 26016
              atomic nucleus 26016
                atom 26016
                  main group element atom 25841
                    p-block element atom 25841
                      carbon group element atom 25441
                        carbon atom 25399
                          organic molecular entity 25399
                            Butylparaben 256
paths to the root